Relimed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 14 Year, 14 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -784.09%
- Ebitda -6481.57%
- Net Worth -53.62%
- Total Assets -97.34%
About Relimed Pharmaceuticals
Relimed Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 January 2011 and has a history of 14 years. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Kamaraj and Veerabadran Rajasekaran serve as directors at the Company.
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U74990TN2011PTC078845
- Company No.
078845
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 2011
- Date of AGM
25 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Relimed Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Veerabadran Rajasekaran  | Director | 01-Oct-2013 | Current |
| Kamaraj | Director | 01-Apr-2019 | Current |
Financial Performance of Relimed Pharmaceuticals.
Relimed Pharmaceuticals Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 784.09% decrease in profit. The company's net worth observed a substantial decline by a decrease of 53.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Relimed Pharmaceuticals?
In 2018, Relimed Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sunglow Lifescience Private LimitedKamaraj and Veerabadran Rajasekaran are mutual person
Sunglow Pharmaceuticalss Private LimitedKamaraj and Veerabadran Rajasekaran are mutual person
- Adiramedica Private Limited
Veerabadran Rajasekaran is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Relimed Pharmaceuticals?
Unlock and access historical data on people associated with Relimed Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Relimed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Relimed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
